William Humphries Net Worth

The estimated Net Worth of William D. Humphries is at least $3.89 million dollars as of 1 June 2024. Mr. Humphries owns over 4,660 units of Bausch Health Companies Inc stock worth over $183,310 and over the last 8 years he sold BHC stock worth over $91,635. In addition, he makes $3,615,590 as at Bausch Health Companies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Humphries BHC stock SEC Form 4 insiders trading

William has made over 16 trades of the Bausch Health Companies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of BHC stock worth $29,731 on 1 June 2024.

The largest trade he's ever made was exercising 114,055 units of Bausch Health Companies Inc stock on 4 December 2020 worth over $1,640,111. On average, William trades about 7,004 units every 38 days since 2016. As of 1 June 2024 he still owns at least 28,732 units of Bausch Health Companies Inc stock.

You can see the complete history of Mr. Humphries stock trades at the bottom of the page.

William Humphries biography

Mr. William Douglas Humphries is no longer serves as President of Ortho-Dermatologics of the Company effective 12/31/2020. Prior to joining Bausch Health, Mr. Humphries was CEO of Merz North America from March 2012 until December 2016, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. and Merz Pharma Canada, Ltd. Prior to joining Merz, he served as the President of Stiefel, a leader in global dermatology and skin health, where he spearheaded two major acquisitions, and led the global integration of Stiefel into GlaxoSmithKline. Previously, Mr. Humphries held multiple senior executive roles within Allergan, Inc., concluding as Vice President of the U.S. Skincare business. Mr. Humphries has been a director of Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, since January 2012, and has also served as a director of Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, since September 2016.

What is the salary of William Humphries?

As the of Bausch Health Companies Inc, the total compensation of William Humphries at Bausch Health Companies Inc is $3,615,590. There are 4 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.

How old is William Humphries?

William Humphries is 53, he's been the of Bausch Health Companies Inc since . There are 18 older and 4 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.

What's William Humphries's mailing address?

William's mailing address filed with the SEC is C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GA, 30005.

Insiders trading at Bausch Health Companies Inc

Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas et Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.

What does Bausch Health Companies Inc do?

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Complete history of Mr. Humphries stock trades at Aclaris Therapeutics Inc, Clearside Biomedical Inc, STRATA Skin Sciences Inc, Bausch Health Companies Inc et PhaseBio Pharmaceuticals

Bausch Health Companies Inc executives and stock owners

Bausch Health Companies Inc executives and other stock owners filed with the SEC include:

• Joseph Papa,
  Chairman of the Board, Chief Executive Officer
• Paul Herendeen,
  Chief Financial Officer, Executive Vice President
• Joseph C. Papa,
  CEO & Chairman
• Thomas Appio,
  President & Co-Head Bausch + Lomb/International
• William Humphries,
  
• Christina Ackermann,
  Executive Vice President, General Counsel
• Thomas J. Appio,
  Pres & Co-Head Bausch + Lomb/International
• Paul S. Herendeen,
  Exec. VP and Advisor to Chairman & CEO
• Joseph Gordon,
  President & Co-Head Bausch + Lomb/International
• Christina M. Ackermann,
  Exec. VP, Gen. Counsel & Head of Commercial Operations
• Thomas Ross,
  Lead Independent Director
• Russel Robertson,
  Independent Director
• Robert Power,
  Independent Director
• Argeris Karabelas,
  Independent Director
• Sarah Kavanagh,
  Independent Director
• D. Robert Hale,
  Independent Director
• Amy Wechsler,
  Independent Director
• Richard De Schutter,
  Independent Director
• Andrew Charles von Eschenbach,
  Independent Director
• John Paulson,
  Independent Director
• Tom G. Vadaketh,
  Chief Financial Officer
• Frederick J. Munsch,
  Controller & Chief Accounting Officer
• Kelly Webber,
  Sr. VP & Chief HR Officer
• Stacey Williams,
  VP of Marketing
• Michael McMyne,
  VP of Sales
• Arthur J. Shannon,
  Sr. VP and Head of Investor Relations & Communications
• Dr. Robert F. Butz,
  VP of Medical & Scientific Affairs
• Osama A. Eldessouky,
  CFO & Exec. VP
• Christian A Garcia,
  Director
• Frank D. Lee,
  Director
• Mark C. Mc Kenna,
  President, Salix
• Holdings, L.P.Value Act Hol...,
  
• Brett Icahn,
  Director
• Steven D Miller,
  Director
• Tom George Vadaketh,
  EVP, Chief Financial Officer
• Holdings, L.P.Value Act Cap...,
  
• Aimee J. Lenar,
  EVP, US Pharma
• Seana Carson,
  EVP, General Counsel
• David Robert Value Act Hold...,
  
• Sam Eldessouky,
  EVP & Chief Financial Officer
• Frederick Munsch,
  SVP, Controller and CAO
• Robert Spurr,
  President, U.S. Businesses
• Richard Mulligan,
  Director
• John S Barresi,
  SVP, Controller & CAO
• Jean Jacques Charhon,
  EVP, CFO